Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure

NCT02372292 | Completed

• 1 other identifier: Ankararenal
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Although the traditional determinant of renal dysfunction in heart failure was suggested as decreased cardiac output and renal hypo perfusion, recent studies have demonstrated the association of persistent systemic venous congestion and kidney dysfunction. Relief of the congestion has demonstrated to improve renal functions in decompensated heart failure. The current trial was set up to investigate the changes of renal venous impedance and renal arteriolar resistivity indices with diuretic therapy, in patients with congestive renal failure. The investigators asked whether measurement of renal venous impedance index or renal arteriolar resistivity index can guide the practice of diuretic therapy.

Conditions

Cardiorenal Syndrome

Keywords

cardiorenal syndrome, decompensated heart failure, renal resistivity index, venous impedance index, kidney failure

Outcome Measures

Primary Outcomes (1)

• Alterations in the renal arterial resistivity index

  Participants will be followed for the duration of hospital stay, an expected average of 4 weeks.

  during hospitalization, an expected average of 4 weeks.

Secondary Outcomes (1)

• Alterations in the renal venous impedance index

  during hospitalization, an expected average of 4 weeks.

Study Arms (2)

Group 1

ACTIVE COMPARATOR

Patients with type 1 cardiorenal syndrome who had improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.

Drug: intravenous furosemide

Group 2

ACTIVE COMPARATOR

Patients with type 1 cardiorenal syndrome who did not have improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.

Drug: intravenous furosemide

Interventions

intravenous furosemide DRUG

Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion

Also known as: Lasix

Group 1; Group 2

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Decompensated heart failure
• Elevated serum creatinine levels on admission

You may not qualify if:

• Atrial fibrillation
• Obstructive uropathy
• Patients with ascites
• Patients who exposed the potential nephrotoxic drugs in the previous week (metformin, antibiotics, chemotherapeutics, iodinated contrast agents and non-steroidal anti-inflammatory agents)
• Patients who needed positive inotropic agents

Sponsors & Collaborators

• Ankara University: lead

Study Sites (1)

Ankara University School Of Medicine, Department of Cardiology

Ankara, 06230, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Cardio-Renal Syndrome; Renal Insufficiency

Interventions

Furosemide

Condition Hierarchy (Ancestors)

Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Heart Failure; Heart Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Sulfanilamides; Sulfonamides; Amides; Organic Chemicals; Aniline Compounds; Amines; Sulfones; Sulfur Compounds

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: February 13, 2015
• First Posted: February 26, 2015
• Study Start: February 1, 2013
• Primary Completion: June 1, 2015
• Study Completion: June 1, 2015
• Last Updated: June 23, 2015

Record last verified: 2015-06

Locations

TU (1)